Vega O, Cárdenas G, Correa-Rotter R, Alberú J, Morales-Buenrostro LE

Language: English
References: 13
Page: 82-86
PDF size: 103.51 Kb.

ABSTRACT

Introduction. Addition of anti-IL2r monoclonal antibodies (chimeric or humanized) for induction therapy has reduced the frequency of acute rejection (AR). This study compares the impact of type and dosage of induction therapy on frequency of acute rejection and on renal function during the first year post-transplant. Patients and methods. Comparative retrospective study. Kidney transplant recipients (KTR) were divided in three groups according to induction therapy, as follows: (1) Basiliximab in two 20 mg doses, (2) Daclizumab 2 mg/kg in one dose, and (3) Daclizumab 2 mg/kg divided in two doses (1mg/kg each). Groups were paired for age, sex, number of shared haplotypes, and previous transplant history. Primary endpoints were AR episodes, time to first AR, graft loss, and death. Secondary endpoints were SCr (at 3, 6, 9 and 12 months), frequency and type of infection, and cost. Results. There were no baseline differences between groups. Twenty one patients were included in each group. The incidence of AR was similar: 14.2% in group 1, and 9.5% for groups 2 and 3. Two deaths were reported, one in group 1 and another in group 2. Mean SCr was similar between groups. Incidence of infection was 6, 5, and 7 in groups 1 to 3, respectively without a significant difference. The cost was higher in group 1 (p ‹ 0.001). Conclusion. Low dose Daclizumab in one or two doses is equally effective and safe as basiliximab at 12-month follow-up, with inferior cost.

REFERENCES

1. Cibrik DM, Kaplan B, Meier-Kriesche HU. Role of anti-interleukin- 2 receptor antibodies in kidney transplantation. Bio- Drugs 2001; 15: 655-66.

2. Vlad G, Ho EK, Vasilescu ER, et al. Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation. Transpl Immunol 2007;18: 13-21.

3. Van Gelder T, Warle M, Ter Meulen RG. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice? Drugs 2004; 64: 1737-41.

4. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin- 2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 2003; 326: 789-93.

5. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997; 350: 1193-8.

6. Vincenti F, Lantz M, Birnbaum J, et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 1997; 63: 33-8.

7. Vincenti F. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation. Transplant Proc 1999; 31: 2206-7.

8. Vincenti F, Pace D, Birnbaum J, Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant 2003; 3: 50-52.

9. Yan LN, Wang W, Li B, et al. Single-dose daclizumab induction therapy in patients with liver transplantation. World J Gastroenterol 2003; 9: 1881-3.

10. Cuppoletti A, Perez-Villa F, Vallejos I, Roig E. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation. Transplant Proc 2005; 37: 4036-8.

11. Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999; 67: 110-5.

12. Niemeyer G, Koch M, Light S, Kuse ER, Nashan B. Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients. Am J Transplant 2002; 2: 454-60.

13. Pham K, Kraft K, Thielke J, et al. Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection. Transplant Proc 2005; 37: 899-902.